NEW YORK – German startup Osteolabs announced on Monday its first commercialization agreements covering Germany and Turkey.
In Germany, Osteolabs has signed a deal with Eurofins LifeCodexx to commercialize Osteolabs' diagnostic test for the early detection of osteoporosis. The company has reached a similar deal in Turkey with BioGen Medical.
Kiel, Germany-based Osteolabs also said that the test will be used in a comprehensive contract research collaboration with the health department of an undisclosed European army for three years during which more than 1,000 tests will be performed to correlate calcium depletion with intense physical activity and bone fractures in female military staff. According to the company, the collaboration "should allow to further validate the potential of the test for early detection of calcium depletion from the skeleton which could be further used for therapeutic monitoring of osteoporosis medications."
Financial and other terms of the agreements were not disclosed.